Imagine your joint is like a rusty hinge that keeps getting worse because of a constant fire of inflammation. This project uses special cells from the placenta to put out that fire in early-stage patients. For others, it uses smart sensors to fix how they walk, stopping the joint from wearing down in the first place.
Osteoarthritis affects 16% of adults and currently has no disease-modifying treatments to stop joint destruction. This leads to massive healthcare costs and chronic disability.
A clinical-grade allogeneic placental cell therapy (PLX-PAD) and a sensor-based digital training program for post-surgical gait correction.
If you are an ATMP developer dealing with the lack of disease-modifying treatments for arthritis — this project developed PLX-PAD allogeneic cell therapy that reduces inflammation and degeneration in early-stage knee OA.
If you are a MedTech startup dealing with poor recovery outcomes after ACL surgery — this project developed a sensor-based digital movement training system that restores physiological movement to prevent OA.
If you are a clinic dealing with chronic joint disability in 16% of the adult population — this project developed a combined cell therapy and digital training strategy to halt disease progression.
Based on available project data, the specific cost per dose or treatment price is not provided.
The project has successfully characterized and released clinical batches of PLX-PAD cells, confirming batch-to-batch reproducibility, which is a prerequisite for scaling.
Based on available project data, specific patent numbers or licensing terms are not listed, though the project involves 5 industry partners.
The approach uses local injections for cell therapy and sensor-based digital training for post-surgery patients to restore biomechanics.
The project period runs from 2023-01-01 to 2027-12-31, suggesting clinical validation is ongoing through 2027.
The consortium is highly commercially oriented with a 50% industry ratio, consisting of 5 SMEs and 5 other partners across 10 countries. Led by Charité Berlin, the mix of 4 universities and 5 industry players suggests a strong pipeline from clinical research to commercial application.
Contact Charité - Universitätsmedizin Berlin regarding PLX-PAD clinical batch results.
Contact us to explore licensing opportunities for the PLX-PAD cell therapy or digital training sensors.
